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Repeated and preemptive palliative radiotherapy of symptomatic
hepatomegaly in a patient with advanced myelofibrosis
Abstract
BACKGROUND: Patients with advanced myelofibrosis often suffer from symptomatic extramedullary
hematopoiesis in spleen and/or liver. In case of drug-refractory disease splenomegaly is treated
surgically, whereas hepatomegaly is palliated by radiotherapy (RT). CASE REPORT: A 56-year-old
man with advanced and drug-refractory myelofibrosis suffered from extensive hepatomegaly with
severe upper abdominal pain, satiety, weight loss, and fatigue 1.5 years after splenectomy. The patient
was treated periodically with fractionated RT to the liver in order to obtain symptom control and to
prevent severe symptom recurrence. RESULTS: After 2 Gy fractionated RT to a treatment field
encompassing nearly the whole liver, symptoms improved and liver size decreased without severe side
effects. This treatment regimen was successfully conducted 3 times in trimonthly intervals. Because
symptoms recurred periodically, we then continued RT on a preemptive basis in monthly intervals and
with single-dose irradiation. The patient responded well to 1 Gy preemptive single-dose RT to the liver,
but not to 0.5 Gy single-dose partial liver irradiation. CONCLUSION: RT is effective in palliation of
hepatomegaly in advanced myelofibrosis. Even preemptive RT can benefit selected patients with
advanced disease and periodical recurrence of symptoms.
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Zusammenfassung
Hintergrund: Patienten mit fortgeschrittener Osteomye-
lofibrose leiden oft unter symptomatischer extramedullä-
rer Blutbildung in Milz und/oder Leber. Bei medikamen-
tenresistenter Erkrankung wird die Splenomegalie chir-
urgisch behandelt, während Patienten mit Hepatome -
galie palliativ bestrahlt werden. Fallbericht: Ein 56 Jahre
alter Mann mit fortgeschrittener und medikamentenre-
sistenter Osteomyelofibrose litt 1,5 Jahre nach Splenek-
tomie unter ausgeprägter Hepatomegalie mit Ober-
bauchschmerzen, Sättigungsgefühl, Gewichtsverlust und
Abgeschlagenheit. Der Patient erhielt eine periodische
fraktionierte Leberbestrahlung zur Symptomkontrolle
und um einem Rezidiv schwerer Symptome vorzubeu-
gen. Ergebnisse: Nach 2 Gy fraktionierter Radiotherapie
der Leber besserten sich die Symptome, und die Leber
wurde kleiner. Es traten keine schweren Nebenwirkun-
gen auf. Dieses Therapieschema wurde dreimal in drei-
monatlichen Abständen erfolgreich durchgeführt. Da die
Symptome periodisch wiederkehrten, führten wir die
 Radiotherapie (RT) im Folgenden auf präemptiver Basis
fort, mit 1 Gy und 0,5 Gy Einzeldosen in einmonatlichen
Abständen. Der Patient sprach gut auf 1 Gy präemptive
RT der Leber an, nicht aber auf 0,5 Gy Teilleberbestrah-
lung. Schlussfolgerung: Die RT ist wirksam in der Pallia-
tion der Hepatomegalie bei fortgeschrittener Osteomye-
lofibrose. Sogar eine präemptive RT kann einzelnen Pa-
tienten mit fortgeschrittener Erkrankung und periodi-
schem Auftreten von Symptomen nützen.
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Summary
Background: Patients with advanced myelofibrosis often
suffer from symptomatic extramedullary hematopoiesis
in spleen and/or liver. In case of drug-refractory disease
splenomegaly is treated surgically, whereas hepatome -
galy is palliated by radiotherapy (RT). Case Report: A 
56-year-old man with advanced and drug-refractory
myelofibrosis suffered from extensive hepatomegaly
with severe upper abdominal pain, satiety, weight loss,
and fatigue 1.5 years after splenectomy. The patient was
treated periodically with fractionated RT to the liver in
order to obtain symptom control and to prevent severe
symptom recurrence. Results: After 2 Gy fractionated RT
to a treatment field encompassing nearly the whole liver,
symptoms improved and liver size decreased without
 severe side effects. This treatment regimen was success-
fully conducted 3 times in trimonthly intervals. Because
symptoms recurred periodically, we then continued RT
on a preemptive basis in monthly intervals and with sin-
gle-dose irradiation. The patient responded well to 1 Gy
preemptive single-dose RT to the liver, but not to 0.5 Gy
single-dose partial liver irradiation. Conclusion: RT is
 effective in palliation of hepatomegaly in advanced
myelofibrosis. Even preemptive RT can benefit selected
patients with advanced disease and periodical recur-
rence of symptoms.
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Introduction
Myelofibrosis with myeloid metaplasia (MMM) is a myelopro-
liferative disorder in which an as yet unidentified stem cell
 defect leads to cytopenia, bone marrow fibrosis, and ex-
tramedullary hematopoiesis (EMH) [1]. Allogenic stem cell
transplantation is the only therapy that has been shown to
cause remissions in MMM, however, depends on the availabil-
ity of a human leukocyte antigen matching donor. In many
 patients management of MMM is palliative and focuses on op-
timizing cytopenia and symptoms through medication,
splenectomy, and palliative radiotherapy (RT) [2, 3]. Radia-
tion is used in patients with drug-refractory MMM to treat
symptomatic EMH, which can induce organomegaly of spleen
or liver, spinal cord compression, ascites, and/or pleural effu-
sion. Organomegaly of the spleen and/or the liver causes pain,
satiety, weight loss, portal hypertension, and profound fatigue.
Removal of the enlarged spleen in patients with drug-refrac-
tory MMM was shown to decrease plasma volume and im-
prove anemia [2]. Since the publication of this report many
patients with drug-refractory MMM receive splenectomy. In
contrast, hepatomegaly is still the domain of palliative RT. In a
recent report 14 patients with drug-refractory MMM received
palliative RT to the liver with symptomatic relief after 86% of
treatments [4]. Here we report a patient with drug-refractory
MMM and hepatomegaly, who received not only 3 palliative
courses of RT within 6 months, but in addition 4 preemptive
courses of RT in monthly intervals with different fractionated
and single doses of RT and different field sizes.
Case Report
The 57-year-old patient first presented in 2000 when he suffered from
weight loss, fatigue, and cytopenia. Examination of bone marrow aspirate
suggested a myeloproliferative syndrome, most likely myeloid metaplasia
with myelofibrosis. Allogenic stem cell transplantation could not be per-
formed because of lack of an appropriate donor. For 2 years the disease
was controlled by palliative medication with hydroxyurea without need of
blood transfusions. Thereafter the patient suffered from rapidly increa-
sing left upper abdominal pain, weight loss, and exacerbated cytopenias
with repetitive epistaxis. Clinical examination revealed extensive spleno-
megaly. Thereupon a giant spleen was removed with a weight of 2,935 g
(6.47 lb). In the following months the patient’s general con dition, body
weight, and cytopenia improved. The disease remained stable for 1.5 years
until the next deterioration with upper abdominal pain, breathlessness in
supine position, satiety, reduced meal quantities with subsequent nausea
and vomitus, diarrhea, and again progressive weight loss. The patient now
needed periodical blood transfusions to compensate for anemia. Clinically
a giant liver was palpated with liver size extending from the diaphragm to
the right iliac crest; the most likely explanation for this was EMH reloca -
tion to the liver. The patient was referred to our radiation oncology de-
partment for palliative RT of the liver. The first treatment course of RT
was delivered with opposed anterior and posterior fields, a beam energy
of 6 MV and a total dose of 2 Gy in 4 fractions. Irradiation was delivered
twice a week in order to be able to stop RT ahead of schedule in case of
extensive hematological toxicity. The treatment field was determined
clini cally as area of intense abdominal distension and comprised nearly
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the whole liver from the diaphragm to the iliac crest. Abdominal pain and
tension already improved during RT, and improvement lasted for 4 to 5
weeks. Liver size clearly diminished as measured by the same experienced
investigator in finger width below umbilicus (fig. 1 A). Treatment was well
tolerated. No additional red blood cell transfusion was necessary during
or shortly after treatment beyond the biweekly blood transfusions that
3 x 2 Gy 2 x 1 Gy 2 x 0.5 Gy
C
Aug  Dez  Apr  Aug  
liv
er
 s
iz
e 
(fi
ng
er
 w
id
th
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5A
Aug  Dez  Apr  Aug  
ce
lls
 p
er
 v
is
io
n 
fie
ld
0
2
4
6
8
10
12
14
16
18
blasts 
myelocytes 
B
Aug  Dez  Apr  Aug  
Ab
so
lu
te
 V
al
ue
s 
(1
03
 c
el
ls
/l)
0
20
40
60
80 wbc
pmn
thrombocytes
liv
er
 s
iz
e 
(fi
ng
er
 w
id
th
)
ce
lls
 p
er
 v
is
io
n 
fie
ld
Ab
so
lu
te
 V
al
ue
s 
(1
03
 c
el
ls
/l)
Fig. 1. Correlation of morphological and hematological response.  A
Liver size was determined as finger width below umbilicus. No initial liver
size was recorded before third fractionated treatment course with 2 Gy. 
B Absolute values of blasts and myelocytes per visual field as counted by
light microscopy. C Absolute values (103 cells/l) of white blood cells
(wbc), thrombocytes, and premature neutrophils (pmn) as determined by
automated blood cell count.
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the patient needed for symptomatic treatment of anemia at that time. Ex-
pected hematological side effects of RT were a short-term decrease of
white blood cells, immature blood cells, and thrombocytes (fig. 1 C). Of
note, apart of the short-term radiation-induced effects, the mature blood
cell count gradually decreased during the observation period, reflecting
increasing bone marrow depletion in the course of the disease. Because of
weak epistaxis platelets were substituted 11 days after the last fraction.
Differentiation of immature blood cells revealed a drop of blastocytes and
myelocytes indicative for response of EMH in the liver to RT (fig. 1 B),
whereas myelomonocytes responded less (data not shown). We repeated
fractionated RT with 2 Gy in 4 fractions after 3 and 6 months because of
recurrent abdominal symptoms that clinically correlated with increased
liver size. Again the patient experienced good symptomatic and mor -
phologic treatment responses with objective reduction of liver size 
(fig. 1 A). Because symptoms recurred periodically, aggravated rapidly
and even seemed to accelerate, we then decided to continue RT on a pre-
emptive basis. RT was continued with 0.5–1 Gy single doses in monthly in-
tervals when symptoms were still modest. The first preemptive single dose
of 1 Gy was given to the same treatment field, whereas the second 1 Gy
single dose one month later was focused on the upper part of the liver
close to the diaphragm where the patient had the discomfort. Both pre-
emptive treatments were toler ated well and induced satisfactory subjec-
tive and morpholo gical responses. We then reduced the radiation single
dose to 0.5 Gy for the subsequent 2 treatments and again only performed
partial liver irradiation with focus on areas of discomfort. After the first
0.5 Gy single dose the patient experienced only a minimal and short-
 lasting improvement, whereas the second 0.5 Gy single dose did not have
any palliative  effect at all and did not reduce liver size (fig. 1 A). However,
because in the latter situation we reduced dose and treatment field to-
gether we can not determine which of the two factors had more impact on
treatment response. A few weeks after the last liver irradiation, the pati-
ent developed leg palsy and urinary dysfunction due to an infiltrative pro-
cess in the cervical spine. He recovered after palliative RT to the brain
and cervical spine with 5 × 3 Gy. Shortly thereafter, he became refractory
to thrombocyte substitution and died from cerebral hemorrhage.
Discussion
RT is effective for palliation of symptomatic EMH in MMM.
In small series of patients palliative doses of RT (15–30 Gy)
divided into multiple fractions successfully reversed spinal
cord compression [5], while comparatively low doses are ade-
quate in the treatment of EMH-associated pleural (1–2 Gy)
[6] or peritoneal (10–12 Gy) [7] effusion. Abdominal pain and
discomfort due to hepatomegaly may occur in advanced
MMM after splenectomy because EMH relocates from the
spleen into the liver. Tefferi et al. [4] reported a symptomatic
response rate of 86% after palliative RT to the liver in a group
of 14 patients. Because some of these patients had spleno -
megaly and/or ascites in addition to hepatomegaly, they were
treated with a broad range of radiation doses (0.5–10 Gy) and
treatment fields. Of note, the doses given by us (0.5–2 Gy)
compare to the medium dose given by Tefferi et al. (1.5 Gy).
In our case we did not intend to cover the whole liver volume,
presuming that a partial volume reduction would be clini-
cally sufficient. In fact, the treatment field employed by us
 (diaphragm to iliac crest) compares to the upper abdominal
field described by Tefferi et al. for patients without ascites. The
total dose of 9 Gy given to our patient is far below the toler-
ance of liver tissue (TD 5/5 approx. 30 Gy) and/or adjacent
organs within the treatment field. Nevertheless, for preemp-
tive treatments we first reduced dose and then field size be-
cause we did not want to completely eradicate hematopoiesis
in liver and lumbar spine in the situation of advanced bone
marrow depletion. We report for the first time consecutive
preemptive liver irradiation in a patient with advanced MMM
in order to prevent recurrence of severe symptoms. In addi-
tion, in contrast to Tefferi et al. [4] who treated a heteroge-
nous group of patients with a wide range of treatment sched-
ules and treatment fields, we observed a correlation between
dose and treatment field on the one hand and clinical, mor-
phological, and hematological response on the other hand in a
single patient. The patient treated by us benefited from total
doses of 1–2 Gy to the liver in contrast to 0.5 Gy partial liver
irradiation. RT induced a decrease of immature blood cells
 indicating that it was indeed EMH that was targeted by RT in
the liver. Mature and immature blood cell counts correlated
with clinical and morphological response indicating a poten-
tial role of these markers as response marker.
The optimal time point to start palliative treatment is crucial
in the management of palliative patients. The decision for
treatment, among other factors, depends on the severity of
symptoms and the expected side effects. With this report we
demonstrate that repeated palliative RT of the liver is a sim-
ple and effective treatment option for palliation of hepa -
tomegaly in advanced myelodysplasia. Further, in case of good
response, even early preemptive liver irradiation may be bene-
ficial in selected patients.
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